Welcome to the Mid-Year Addendum to Our Payers’ Guide to New FDA Approvals

2019 Payers' Guide Mid-Year Addendum - Foreword
American Health & Drug Benefits is pleased to bring you the first-ever mid-year addendum to our annual Payers’ Guide to New FDA Approvals. With the growing number of FDA approvals of new drugs and new indications in the past few years, publishing a mid-year addendum to the annual guide aims to provide payers, providers, Pharmacy & Therapeutics committees, and other healthcare stakeholders a quick overview of some of the novel pharmaceuticals already approved by the US Food and Drug Administration (FDA) in 2019, in anticipation of many more to come before the end of the year.

This mid-year tool offers a quick, evidence-based resource for medical and pharmacy directors for some of the new FDA approvals to help guide their benefit design decision-making and the development of formulary and other drug coverage criteria.

This new mid-year Addendum includes a select sample of comprehensive updates on some of the key new drugs approved by the FDA in 2019, as well as several new and important indications for drugs that are already on the market. This new feature provides a preview to the full annual guide that will be published early next year.

We hope you find this new publishing effort a useful tool for applying up-to-date information on new pharmaceuticals to benefit design decisions and patient care.


EDITOR’S NOTE: The FDA continues to make changes to the prescribing information of many drugs on an ongoing basis. The information in this Addendum is based on each drug’s prescribing information up to July 10, 2019. The Publisher and the Editors are not responsible for any inaccuracies stemming from labeling changes, new approvals, or company updates that became available after that date. Readers are advised to review the most recent prescribing information for any future updates and revisions.

Last modified: August 13, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME